– USA, WA – Impel NeuroPharma, a Seattle-based clinical-stage biotechnology company developing first-in-class intranasal drug treatments, announced today the appointment of Timothy S. Nelson as Independent Director of the Board of Directors.
Mr. Nelson has over 20 years of experience with drug delivery, medical devices and drug device combinations. Most recently, Mr. Nelson served as MAP Pharmaceuticals’ President and CEO and as a member of its Board of Directors from April 2005 until March 2013. MAP was acquired by Allergan for $960 million. During that time, Mr. Nelson led the company through its initial public offering and developed LEVADEX, an inhaled dihydroergotamine for migraine. Prior to MAP, he served as Senior Vice President of Commercial and Business Development at DURECT Corporation and has held various senior management positions with Medtronic, including Business Director of the Neurological Division for Europe, the Middle East and Africa, and as Manager of Drug Delivery Ventures.
Mr. Nelson has served on several boards, including Chairman of the Board of Civitas, a private biopharmaceutical company focused on treating undermet medical needs in neurological indications from December 2013 to October 2014. The company was acquired by Acorda Therapeutics for $525 million that year. He also served on the Board of Directors of Surmodics, a public medical technology company, from February 2014 to March 2015. Mr. Nelson holds a Master’s degree in Management with distinction from the Kellogg Graduate School of Management at Northwestern University and a Bachelors in Chemical Engineering from the University of Minnesota.
“We are very excited to bring Tim onto Impel’s Board of Directors. Tim brings a deep knowledge of both medical devices and pharmaceutical products that will help Impel drive clinical development of our drug-device combination products,” said John Hoekman, Impel’s Founder & CEO. “Impel is developing nasally administered products to treat migraine, Parkinson’s, and Alzheimer’s disease. Tim’s experience and leadership will help Impel advance these therapies through clinical testing and into the hands of patients.”
“Impel’s unique, cutting-edge technology has the potential to make a substantial step forward in more effective delivery of drugs which can mean better outcomes for millions of patients who are underserved by existing therapies,” Mr. Nelson said. “I am very pleased to be able to contribute to Impel’s mission and growth.”
About POD technology
Impel NeuroPharma’s POD™ nasal drug delivery platform is designed to deliver drugs to the upper nasal cavity for improved biodistribution. By delivering therapeutics to the upper nasal cavity, the POD nasal delivery platform takes advantage of the vascular rich olfactory region for improved bioavailability and has the potential to target the brain via the olfactory and trigeminal nerves. Delivery of therapeutically meaningful levels of drugs may allow for development of more effective drugs and expand the range of treatment options available to patients.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel NeuroPharma has developed a novel drug delivery platform, the POD™ technology, that administers drug to the deep nasal cavity to improve the biodistribution of many drugs. Impel NeuroPharma’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device.
For more information : http://www.impelnp.com
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.